Medication info
Enpistar Tablet 80/5mg

Enpistar Tablet 80/5mg

Prescription medicationOral
Ingredient · strength
Telmisartan Powder 23.9%›334.72mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tablet
Manufacturer / importer
Daehan New Pharm Co., Ltd.
Appearance
It is a double tablet that is oval-shaped and biconvex in appearance, colored white and light gray.
Packaging
30 tablets (10 tablets/PTPX3)
Approval status
Active

MFDS item code 201605824 · Approved 2016.09.30 · Insurance code 669906980

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (telmisartan or amlodipine). However, if blood pressure is not controlled with the individual components as described below, a direct switch to this medicine may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. ○ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ○ Elderly patients: The usual amlodipine regimen is recommended for elderly patients, but caution should be exercised when increasing the dose (see section ‘3. Patients requiring careful administration’). In elderly patients aged 75 years or older, amlodipine clearance is reduced; therefore, start treatment at a low dose and increase the dose gradually.
Child dose
○ Pediatrics: The safety and efficacy of this medicine have not been established in pediatric patients 18 years of age or younger; therefore, its use is not recommended.

Ingredients

Manufacturer
Daehan New Pharm Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used for effectively controlling blood pressure in patients with essential hypertension who do not achieve adequate blood pressure control with monotherapy of telmisartan or amlodipine.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (telmisartan or amlodipine). However, if blood pressure is not controlled with the individual components as described below, a direct switch to this medicine may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. ○ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ○ Elderly patients: The usual amlodipine regimen is recommended for elderly patients, but caution should be exercised when increasing the dose (see section ‘3. Patients requiring careful administration’). In elderly patients aged 75 years or older, amlodipine clearance is reduced; therefore, start treatment at a low dose and increase the dose gradually.

Child dose

○ Pediatrics: The safety and efficacy of this medicine have not been established in pediatric patients 18 years of age or younger; therefore, its use is not recommended.

Precautions

This medication can cause serious harm to the fetus, especially during the second and third trimesters of pregnancy, so it should not be used by pregnant women or women who may become pregnant. This medication should not be administered to patients with certain conditions, such as liver impairment, obstructive biliary disease, severe hypotension, cardiogenic shock, and unstable heart failure after acute myocardial infarction. Patients with primary aldosteronism or aortic stenosis, and hypertrophic obstructive cardiomyopathy require special caution when using this medication. As this medication is metabolized by the liver and excreted in bile, dosage adjustment and caution are necessary in patients with impaired liver function. Patients with gastrointestinal disorders may experience gastrointestinal-related side effects, so it should be administered cautiously. In patients with renal function impairment or renal artery hypertension, there is a risk of worsening kidney function or hypotension, necessitating regular blood tests and monitoring. Elderly patients may exhibit sensitive reactions, so dosing should be adjusted slowly with caution. This medication can significantly reduce blood pressure; if hypotensive symptoms occur, the patient should be laid down immediately and receive fluid therapy if necessary. Hyperkalemia may occur, hence, caution is necessary if potassium supplements or medications containing potassium are taken concurrently. This medication can cause drowsiness or dizziness; therefore, caution should be exercised while driving or operating machinery. There may be interactions with other medications, so it is important to inform healthcare providers of any medications currently being taken. Safety and efficacy have not been established in children, so use is not recommended. In case of overdose, severe hypotension and cardiovascular side effects may occur, so appropriate treatment should be sought immediately at a medical facility. When storing this medication, keep it out of reach of children, away from moisture, and take it immediately after opening the package.

Side effects

  • Dizziness
  • peripheral edema
  • syncope
  • upper respiratory infection
  • pharyngitis
  • sinusitis
  • urinary tract infection
  • cystitis
  • sepsis
  • anemia
Show 101 more
  • thrombocytopenia
  • eosinophilia
  • leukocytopenia
  • hypersensitivity
  • anaphylactic reaction
  • hyperkalemia
  • hypoglycemia
  • hyponatremia
  • hyperglycemia
  • depression
  • insomnia
  • mood changes
  • anxiety
  • confusion
  • drowsiness
  • headache
  • migraine
  • paresthesia
  • sensory loss
  • dysgeusia
  • tremor
  • extrapyramidal disorder
  • muscle rigidity
  • visual impairment
  • diplopia
  • vertigo
  • tinnitus
  • palpitations
  • bradycardia
  • tachycardia
  • myocardial infarction
  • ventricular tachycardia
  • arrhythmia
  • atrial fibrillation
  • flushing
  • hypotension
  • orthostatic hypotension
  • vasculitis
  • cough
  • dyspnea
  • rhinitis
  • changes in bowel habits
  • diarrhea
  • constipation
  • abdominal pain
  • dyspepsia
  • nausea
  • vomiting
  • dry mouth
  • gingival hyperplasia
  • abdominal discomfort
  • pancreatitis
  • gastritis
  • impaired liver function
  • liver dysfunction
  • hepatitis
  • jaundice
  • increased liver enzymes
  • pruritus
  • hyperhidrosis
  • rash
  • hair loss
  • purpura
  • skin discoloration
  • eczema
  • erythema
  • angioedema
  • toxic skin rash
  • drug eruption
  • urticaria
  • erythema multiforme
  • exfoliative dermatitis
  • Stevens-Johnson syndrome
  • photosensitivity reaction
  • toxic epidermal necrolysis
  • joint swelling
  • muscle cramps
  • arthralgia
  • myalgia
  • low back pain
  • limb pain
  • tendon pain
  • renal dysfunction
  • urination disorders
  • frequency of urination
  • nocturia
  • erectile dysfunction
  • gynecomastia
  • edema
  • asthenia
  • fatigue
  • chest pain
  • malaise
  • influenza-like illness
  • increased liver enzymes
  • increased blood creatinine
  • weight gain
  • weight loss
  • increased blood uric acid
  • increased blood creatine phosphokinase
  • decreased hemoglobin

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that prevents light exposure. Additionally, it is important to store it at room temperature between 1 degree and 30 degrees Celsius to avoid damage.

Appearance and packaging

Appearance

It is a double tablet that is oval-shaped and biconvex in appearance, colored white and light gray.

Package unit

30 tablets (10 tablets/PTPX3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.